E-MAIL: [email protected]
Xinfuda Announces Participation in FCE Pharma 2026 in São Paulo
072026.05
What FDA’s 503B Proposal Means for Biopharmaceuticals
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
062026.05
Reusable Pen Device with Cartridge Replacement for Biopharma Companies
Copyright © Shijiazhuang Xinfuda Medical Packaging Co., Ltd. All Rights
Reserved Powered by
MAKE AN ENQUIRY
